{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:29:07Z","timestamp":1791311347529,"version":"4.3.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The prevalence of myasthenia gravis is increasing in many countries, including Asia. As treatment options expand, population-based information about the disease burden can inform health technology assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a population-based retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Death Registry to describe the epidemiology, disease burden and treatment patterns of generalized myasthenia gravis (gMG) from 2009 to 2019. Episodes of hepatitis B virus (HBV) infection or reactivation were explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years. The female:male ratio was 1.3:1. Frequently reported co-morbidities were hypertension (32\u201334% of patients), diabetes mellitus (16\u201321%) and malignancies (12\u201317%). The prevalence of patients with gMG increased annually from 6.83\/100,000 population in 2009 to 11.18\/100,000 population in 2019 (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001). There was no temporal trend in all-cause fatality rates (range 2.76\u20133.79\/100 patients annually) or gMG incidence rates (2.4\u20133.17\/100,000 population annually). First-line treatment was with pyridostigmine (82%), steroids (58%), and azathioprine (11%). There was minimal change in treatment patterns over time. Among 147 new HBV infections, 32 (22%) received \u22654\u2009weeks of antiviral therapy suggesting chronic infection. The HBV reactivation rate was 7.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The epidemiology of gMG in Taiwan is evolving rapidly, with higher prevalence rates and increasing involvement of older age-groups suggesting a growing burden of disease and associated healthcare costs. HBV infection or reactivation may pose a previously unrecognized recognized risk for patients with gMG receiving immunosuppressants.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1203679","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T19:40:31Z","timestamp":1687635631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan"],"prefix":"10.3389","volume":"14","author":[{"given":"Keira Joann","family":"Herr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Pei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari","year":"2021","journal-title":"J Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/jnnp.2008.152637","article-title":"Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan","volume":"80","author":"Matsui","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jhep.2015.03.013","article-title":"Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan","volume":"63","author":"Chen","year":"2015","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/17571472.2010.11493315","article-title":"An overview of the healthcare system in Taiwan","volume":"3","author":"Wu","year":"2010","journal-title":"London J Prim Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ije\/29.2.336","article-title":"Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics","volume":"29","author":"Lu","year":"2000","journal-title":"Int J Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in Taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/ane.13596","article-title":"Epidemiological profile of myasthenia gravis in South Korea using the national health insurance database","volume":"145","author":"Park","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/17474124.2020.1774364","article-title":"Hepatitis B reactivation: diagnosis and management","volume":"14","author":"Huang","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1440-1843.2010.01822.x","article-title":"Systemic corticosteroid and reactivation of chronic hepatitis B","volume":"15","author":"Lai","year":"2010","journal-title":"Respirology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.vaccine.2017.07.046","article-title":"Hepatitis B vaccines: WHO position paper, July 2017 \u2013 recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","article-title":"Data resource profile: the national health insurance research database (NHIRD)","volume":"40","author":"Lin","year":"2018","journal-title":"Epidemiol Health"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1203679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T19:40:35Z","timestamp":1687635635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1203679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":23,"alternative-id":["10.3389\/fneur.2023.1203679"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1203679","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"article-number":"1203679"}}